In an effort to support global initiatives to contain the spread of the new coronavirus (COVID-19), the Academy is presenting Spring 2020 events through online platforms and some of our previously scheduled events are being postponed to a later date. Please check our events listing for the latest information and contact our Customer Service team with any additional questions. For Academy programs and resources about COVID-19, click here.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.


Immunology and Pathogenesis of Viral Hemorrhagic Fevers

Edited by Edited by Aftab Ansari, Abdul Jabbar, Tristram Parslow, and Rafi Ahmed (Emory University, Atlanta, GA)
Immunology and Pathogenesis of Viral Hemorrhagic Fevers

Published: September 2009

Volume 1171

In this Annals volume leaders in the field from universities, industry, the National Institutes of Health, and the Centers for Disease Control present up-to-date information on the biology, pathogenesis, epidemiology and immunology of pathogenic hemorrhagic fever viruses.
Learn More

Based on a conference sponsored by the Comprehensive Center for Translational Research on Human Immunology and Biodefense at the Emory Vaccine Center (EVC), Emory University. The EVC is one of eight institutions that received funding from the National Institutes of Health to establish a Comprehensive Center for Translational Research on Human Immunology and Bio-defense (CCHI). The long-term goal of the CCHI program is the translation of research into clinical applications in humans. Immediate goals are to support basic and translational research on human immunological responses to NIAID Category A, B or C priority pathogens, their toxins, or other emerging or re-emerging infectious diseases.

Special online volume with